Fresnay Stéphanie, Garnache-Ottou Francine, Plumas Joel, Seilles Estelle, Tiberghien Pierre, Saas Philippe
INSERM E0119, Etablissement Français du Sang Bourgogne Franche-Comté, MEN EA2284, Université de Franche-Comté, Besancon, France.
Transpl Immunol. 2003 Jul-Sep;11(3-4):259-66. doi: 10.1016/S0966-3274(03)00053-4.
Recent evidence suggests that recipient as well as donor dendritic cell (DC) subsets are implicated in hematopoietic engraftment, graft-vs.-host disease occurrence, immune reconstitution and graft-vs.-leukemia effects observed after allogeneic hematopoietic cell transplantation. Although further data are needed to better understand the precise role of different DC subsets, strategies based on their manipulation to obtain tolerogenic DC can be envisaged. Here, we propose that DC blocked in an immature stage, using immunosuppressive agents, or lymphoid DC can be adequate candidates to control the alloreactive conflict post-allograft.
近期证据表明，在异基因造血细胞移植后观察到的造血植入、移植物抗宿主病发生、免疫重建及移植物抗白血病效应中，受者以及供者的树突状细胞（DC）亚群均有涉及。尽管需要更多数据来更好地理解不同DC亚群的确切作用，但可以设想基于对其进行操控以获得耐受性DC的策略。在此，我们提出，使用免疫抑制剂阻断于未成熟阶段的DC或淋巴样DC可能是控制移植后同种异体反应性冲突的合适候选者。
